

Repertoire Immune Medicines
PRESS RELEASE – September 2020 Citi
Draft 28 August 2020

Repertoire Immune Medicines to Present at the Citi 15th Annual BioPharma Virtual Conference

CAMBRIDGE, MA, August 31, 2020 – [Repertoire Immune Medicines](#), a clinical-stage biotechnology company focused on decoding and deploying the immune system across multiple major diseases, will present at Citi's 15th Annual BioPharma Virtual Conference on Tuesday, September 8, 2020 at 9:30 am ET.

About Repertoire Immune Medicines

Repertoire Immune Medicines is a clinical-stage biotechnology company working to unleash the remarkable power of the human immune system to prevent, treat or cure cancer, autoimmune conditions and infectious diseases. The company is founded on the premise that the repertoire of T cell receptor-antigen codes that drive health and disease represents one of the greatest opportunities for innovation in medical science. The company harnesses and deploys the intrinsic ability of T cells to prevent and cure disease. Repertoire scientists created and developed a suite of technologies for its DECODE discovery and DEPLOY product platforms that allow in-depth characterization of the immune synapse and the ability to rationally design and clinically develop multi-clonal immune medicines. The company is currently conducting a clinical trial using autologous T cells primed against cancer antigens and tethered to IL-15. To learn more about Repertoire Immune Medicines, please visit our website: www.repertoire.com and follow us on LinkedIn and Twitter.

Investor Contact:

Kendall Investor Relations
Carlo Tanzi, Ph.D.
ctanzi@kendallir.com

Media Contact:

Repertoire Immune Medicines
Kate Niazi-Sai
kniaisai@repertoire.com